LAUSR

We read an article entitled “The relationship between glucose homeostasis status and prostate size in aging Chinese males with benign prostatic hyperplasia” in the journal World Journal of Urology [1]. The author analyzes the relationship between prostate size and blood glucose levels in patients with BPH undergoing transurethral resection of the prostate (TURP). The study found that there was more large-sized prostate volume in BPH patients with higher blood glucose levels. The authors hold that hyperglycemia may play an important role in prostate growth. However, we thought that if the study can add the prostate-specific antigen (PSA) and International Prostate Symptom Score (IPSS) data to analysis, it would have more clinical meanings. As we know, for the BPH patients undergoing TURP, PSA is a routine to screen prostate carcinoma as well as is associated with hyperplasia of the prostate and its size. A previous study also found that PSA levels were related to prostate size [2]. IPSS is also an important reference for the patient of BPH to select TURP. A study found that IPSS is not positively associated with prostate volume [2]. We can know the blood glucose levels cannot affect the IPSS in the BPH patients even if it is associated with prostate size. However, the two important clinical measurement indexes were not recorded in the study, which did not allow the readers to understand the clinical significance further.